Impact of interleukin-18 polymorphisms-607 and -137 on clinical characteristics of renal cell carcinoma patients

Human Immunology

Volumn 71, Issue 3, 2010, Pages 309-313

  Sáenz López, Pablo ^a   Carretero, Rafael ^a   Vazquez, Fernando ^a   Martin, Javier ^b   Sánchez, Elena ^b   Tallada, Miguel ^a   Garrido, Federico ^a   Cózar, José Manuel ^a   Ruiz Cabello, Francisco ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

Clinical characteristics; IL 18; Polymorphism; RCC

Indexed keywords

GENOMIC DNA; INTERLEUKIN 18;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CLEAR CELL CARCINOMA; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-18; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, GENETIC; PROGNOSIS; SPAIN; SURVIVAL ANALYSIS;

EID: 76949106093     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2009.11.010     Document Type: Article

References (42)

1. Mulders P., Figlin R., deKernion J.B., Wiltrout R., Linehan M., Parkinson D., et al. Renal cell carcinoma: Recent progress and future directions. Cancer Res 57 (1997) 5189-5195
2. Nelson D., and Ganss R. Tumor growth or regression: Powered by inflammation. J Leukoc Biol 80 (2006) 685-690
3. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
4. Balkwill F., Charles K.A., and Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7 (2005) 211-217
5. Sáenz-López P., Carretero R., Cózar J.M., Romero J.M., Canton J., Vilchez J.R., et al. Polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer 8 (2008) 382
6. Romero J.M., Sáenz-López P., Cózar J.M., Carretero R., Canton J., Vazquez F., et al. A polymorphism in the interleukin-10 promoter affects the course of disease in patients with clear-cell renal carcinoma. Hum Immunol 70 (2009) 60-64
7. Kawai Y., Sakano S., Korenaga Y., Eguchi S., and Naito K. Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas. Eur Urol 52 (2007) 1147-1155
8. Okamura H., Tsutsi H., Komatsu T., Yutsudo M., Hakura A., Tanimoto T., et al. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 378 (1995) 88-91
9. + T lymphocytes. J Immunol 160 (1998) 3642-3647
10. Tominaga K., Yoshimoto T., Torigoe K., Kurimoto M., Matsui K., Hada T., et al. IL-12 synergizes with IL-18 or IL-1β for IFN-γ production from human T cells. Int Immunol 12 (2000) 151-160
11. - cells. J Immunol 160 (1998) 4738-4746
12. Micallef M.J., Tanimoto T., Kohno K., Ikeda M., and Kurimoto M. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma. Cancer Res 57 (1997) 4557-4563
13. Chang C.Y., Lee J., Kim E.Y., Park H.J., Kwon C.H., Joh J.W., et al. Intratumoral delivery of IL-18 naked DNA induces T-cell activation and Th1 response in a mouse hepatic cancer model. BMC Cancer 7 (2007) 87
14. Cho D., Kim T.G., Lee W., Hwang Y.I., Cho H.I., Han H., et al. Interleukin-18 and the costimulatory molecule B7-1 have a synergistic anti-tumor effect on murine melanoma; implication of combined immunotherapy for poorly immunogenic malignancy. J Invest Dermatol 114 (2000) 928-934
15. Park H., Byun D., Kim T.S., Kim Y.I., Kang J.S., Hahm E.S., et al. Enhanced IL-18 expression in common skin tumors. Immunol Lett 79 (2001) 215-219
16. Udagawa N., Horwood N.J., Elliott J., Mackay A., Owens J., Okamura H., et al. Interleukin-18 (interferon-gamma inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. J Exp Med 185 (1997) 1005-1012
17. Ye Z.B., Ma T., Li H., Jin X.L., and Xu H.M. Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. World J Gastroenterol 13 (2007) 1747-1751
18. Eissa S.A., Zaki S.A., El-Maghraby S.M., and Kadry D.Y. Importance of serum IL-18 and RANTES as markers for breast carcinoma progression. J Egypt Natl Canc Inst 17 (2005) 51-55
19. Cho D., Song H., Kim Y.M., Houh D., Hur D.Y., Park H., et al. Endogenous interleukin-18 modulates immune escape of murine melanoma cells by regulating the expression of Fas ligand and reactive oxygen intermediates. Cancer Res 60 (2000) 2703-2709
20. Bubenik J. Tumor MHC class I downregulation and immunotherapy. Oncol Rep 10 (2003) 2005-2008
21. Kim J., Shao Y., Kim S.Y., Kim S., Song H.K., Jeon J.H., et al. Hypoxia-induced IL-18 increases hypoxia-inducible factor-1alpha expression through a Rac1-dependent NF-kappaB pathway. Mol Biol Cell 19 (2008) 433-444
22. Kim J., Kim C., Kim T.S., Bang S.I., Yang Y., Park H., et al. IL-18 enhances thrombospondin-1 production in human gastric cancer via JNK pathway. Biochem Biophys Res Commun 344 (2006) 1284-1289
23. Park S., Cheon S., and Cho D. The dual effects of interleukin-18 in tumor progression. Cell Mol Immunol 4 (2007) 329-335
24. Giedraitis V., He B., Huang W.X., and Hillert J. Cloning and mutation analysis of the human IL-18 promoter: A possible role of polymorphisms in expression regulation. J Neuroimmunol 112 (2001) 146-152
25. Lam J.S., Shvarts O., Leppert J.T., Pantuck A.J., Figlin R.A., and Belldegrun A.S. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 174 (2005) 466-472
26. Martin R.J., Savage D.A., Carson D.J., Maxwell A.P., and Patterson C.C. Interleukin 18 promoter polymorphisms are not strongly associated with type I diabetes in a UK population. Genes Immun 6 (2005) 171-174
27. Pratesi C., Bortolin M.T., Bidoli E., Tedeschi R., Vaccher E., Dolcetti R., et al. Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunol Immunother 55 (2006) 23-30
28. Pratesi C., Bortolin M.T., Bidoli E., Tedeschi R., Vaccher E., Dolcetti R., et al. Inflammation and chronic prostatic diseases: Evidence for a link?. Eur Urol 52 (2007) 964-972
29. Cozar J.M., Romero J.M., Aptsiauri N., Vazquez F., Vilchez J.R., Tallada M., et al. High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum Immunol 68 (2007) 698-704
30. Farhat K., Hassen E., Bouzgarrou N., Gabbouj S., Bouaouina N., and Chouchane L. Functional IL-18 promoter gene polymorphisms in Tunisian nasopharyngeal carcinoma patients. Cytokine 43 (2008) 132-137
31. Liu Y., Lin N., Huang L., Xu Q., and Pang G. Genetic polymorphisms of the interleukin-18 gene and risk of prostate cancer. DNA Cell Biol 26 (2007) 613-618
32. Nikiteas N., Yannopoulos A., Chatzitheofylaktou A., and Tsigris C. Heterozygosity for interleukin-18 -607A/C polymorphism is associated with risk for colorectal cancer. Anticancer Res 27 (2007) 3849-3853
33. Campa D., Hung R.J., Mates D., Zaridze D., Szeszenia-Dabrowska N., Rudnai P., et al. Lack of association between -251 T > A polymorphism of IL8 and lung cancer risk. Cancer Epidemiol Biomarkers Prev 14 (2005) 2457-2458
34. Vairaktaris E., Serefoglou Z.C., Yapijakis C., Agapi C., Vassiliou S., Nkenke E., et al. The interleukin-18 -607A/C polymorphism is not associated with risk for oral cancer. Anticancer Res 27 (2007) 4011-4014
35. Nakanishi K., Yoshimoto T., Tsutsui H., and Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 12 (2001) 53-72
36. Vidal-Vanaclocha F., Mendoza L., Telleria N., Salado C., Valcárcel M., Gallot N., et al. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev 25 (2006) 417-434
37. Cho M.L., Jung Y.O., Moon Y.M., Min S.Y., Yoon C.H., Lee S.H., et al. Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways. Immunol Lett 103 (2006) 159-166
38. Jiang D.F., Liu W.L., Lu Y.L., Qiu Z.Y., and He F.C. Function of IL-18 in promoting metastasis of lung cancer. Zhonghua Zhong Liu Za Zhi 25 (2003) 348-352
39. Jung M.K., Song H.K., Kim K.E., Hur D.Y., Kim T., Bang S., et al. IL-18 enhances the migration ability of murine melanoma cells through the generation of ROI and the MAPK pathway. Immunol Lett 107 (2006) 125-130
40. Langley R.R., Carlisle R., Ma L., Specian R.D., Gerritsen M.E., and Granger D.N. Endothelial expression of vascular cell adhesion molecule-1 correlates with metastatic pattern in spontaneous melanoma. Microcirculation 8 (2001) 335-345
41. Balkwill F. Chemokine biology in cancer. Semin Immunol 15 (2003) 49-55
42. Kung A.L., Zabludoff S.D., France D.S., Freedman S.J., Tanner E.A., Vieira A., et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6 (2004) 33-43